{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:25:06Z","timestamp":1792758306130,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12282-022-01422-5","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T21:03:17Z","timestamp":1671310997000},"page":"282-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4\/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-5577","authenticated-orcid":false,"given":"Terufumi","family":"Kawamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Shikama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Imano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Sekii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Tonari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobue","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"key":"1422_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209\u201319.","journal-title":"N Engl J Med"},{"key":"1422_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541\u20137.","journal-title":"Ann Oncol"},{"key":"1422_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116\u201324.","journal-title":"JAMA Oncol"},{"key":"1422_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.annonc.2022.03.003","volume":"33","author":"GF Fleming","year":"2022","unstructured":"Fleming GF, Pagani O, Regan MM, Walley BA, Francis PA. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2022;33:658.","journal-title":"Ann Oncol"},{"key":"1422_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.adro.2019.03.011","volume":"4","author":"M Chowdhary","year":"2019","unstructured":"Chowdhary M, Sen N, Chowdhary A, Usha L, Cobleigh MA, Wang D, et al. Safety and efficacy of palbociclib and radiation therapy in patients with metastatic breast cancer: initial results of a novel combination. Adv Radiat Oncol. 2019;4:453\u20137.","journal-title":"Adv Radiat Oncol"},{"key":"1422_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.breast.2019.05.001","volume":"46","author":"E Ippolito","year":"2019","unstructured":"Ippolito E, Greco C, Silipigni S, Dell\u2019Aquila E, Petrianni GM, Tonini G, et al. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: preliminary assessment of toxicity. Breast. 2019;46:70\u20134.","journal-title":"Breast"},{"key":"1422_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41416-020-0957-9","volume":"123","author":"A Beddok","year":"2020","unstructured":"Beddok A, Xu HP, Henry AA, Porte B, Fourquet A, Cottu P, et al. Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature. Br J Cancer. 2020;123:905\u20138.","journal-title":"Br J Cancer"},{"key":"1422_CR8","doi-asserted-by":"publisher","first-page":"13589","DOI":"10.1038\/s41598-020-70430-2","volume":"10","author":"AE Guerini","year":"2020","unstructured":"Guerini AE, Pedretti S, Salah E, Simoncini EL, Maddalo M, Pegurri L, et al. A single-center retrospective safety analysis of cyclin-dependent kinase 4\/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Sci Rep. 2020;10:13589.","journal-title":"Sci Rep"},{"key":"1422_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.radonc.2018.09.020","volume":"131","author":"T Kawamoto","year":"2019","unstructured":"Kawamoto T, Shikama N, Sasai K. Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment. Radiother Oncol. 2019;131:240\u20131.","journal-title":"Radiother Oncol"},{"key":"1422_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.rpor.2019.03.001","volume":"24","author":"JA Messer","year":"2019","unstructured":"Messer JA, Ekinci E, Patel TA, Teh BS. Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: a case report. Rep Pract Oncol Radiother. 2019;24:276\u201380.","journal-title":"Rep Pract Oncol Radiother"},{"key":"1422_CR11","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.21873\/anticanres.14534","volume":"40","author":"UM Nasir","year":"2020","unstructured":"Nasir UM, Mozeika AM, Sayan M, Jan I, Kowal N, Haffty B, et al. Severe gastrointestinal mucositis following concurrent palbociclib and palliative radiation therapy. Anticancer Res. 2020;40:5291\u20134.","journal-title":"Anticancer Res"},{"key":"1422_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100939","volume":"14","author":"S David","year":"2021","unstructured":"David S, Ho G, Day D, Harris M, Tan J, Goel S, et al. Enhanced toxicity with CDK 4\/6 inhibitors and palliative radiotherapy: non-consecutive case series and review of the literature. Transl Oncol. 2021;14: 100939.","journal-title":"Transl Oncol"},{"key":"1422_CR13","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ijrobp.2018.07.192","volume":"102","author":"CL Lee","year":"2018","unstructured":"Lee CL, Oh P, Xu ES, Ma Y, Kim Y, Daniel AR, et al. Blocking cyclin-dependent kinase 4\/6 during single dose versus fractionated radiation therapy leads to opposite effects on acute gastrointestinal toxicity in mice. Int J Radiat Oncol Biol Phys. 2018;102:1569\u201376.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1422_CR14","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ijrobp.2009.10.015","volume":"77","author":"GR Borst","year":"2010","unstructured":"Borst GR, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Bengua G, et al. Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters. Int J Radiat Oncol Biol Phys. 2010;77:1596\u2013603.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1422_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0167-8140(93)90026-5","volume":"26","author":"CH Newcomb","year":"1993","unstructured":"Newcomb CH, Van Dyk J, Hill RP. Evaluation of isoeffect formulae for predicting radiation-induced lung damage. Radiother Oncol. 1993;26:51\u201363.","journal-title":"Radiother Oncol"},{"key":"1422_CR16","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/0360-3016(82)90459-X","volume":"8","author":"GW Barendsen","year":"1982","unstructured":"Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981\u201397.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1422_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1422_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.clbc.2020.05.013","volume":"20","author":"I Ratosa","year":"2020","unstructured":"Ratosa I, Orazem M, Scoccimarro E, Steinacher M, Dominici L, Aquilano M, et al. Cyclin-dependent kinase 4\/6 inhibitors combined with radiotherapy for patients with metastatic breast cancer. Clin Breast Cancer. 2020;20:495\u2013502.","journal-title":"Clin Breast Cancer"},{"key":"1422_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.breast.2021.10.001","volume":"60","author":"KN Kim","year":"2021","unstructured":"Kim KN, Shah P, Clark A, Freedman GM, Dastgheyb S, Barsky AR, et al. Safety of cyclin-dependent kinase4\/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer. Breast. 2021;60:163\u20137.","journal-title":"Breast"},{"key":"1422_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.07.005","author":"A Al-Rashdan","year":"2022","unstructured":"Al-Rashdan A, Quirk S, Roumeliotis M, Abedin T, Amaro CP, Barbera L, et al. Radiation therapy with cyclin-dependent kinase 4\/6 inhibitors: a multi-institutional safety and toxicity study. Int J Radiat Oncol Biol Phys. 2022. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.005.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1422_CR21","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.annonc.2021.03.062","volume":"32","author":"YS Yap","year":"2021","unstructured":"Yap YS, Kim SB, Chiu JWY, Lim E, Broom R, Liu Z, et al. 48P Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE. Ann Oncol. 2021;32:S41\u20132.","journal-title":"Ann Oncol"},{"key":"1422_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ctro.2020.11.010","volume":"26","author":"C Bosacki","year":"2021","unstructured":"Bosacki C, Bouleftour W, Sotton S, Vallard A, Daguenet E, Ouaz H, et al. CDK 4\/6 inhibitors combined with radiotherapy: a review of literature. Clin Transl Radiat Oncol. 2021;26:79\u201385.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1422_CR23","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1200\/JCO.2007.15.3312","volume":"26","author":"A Fairchild","year":"2008","unstructured":"Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008;26:4001\u201311.","journal-title":"J Clin Oncol"},{"key":"1422_CR24","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.21873\/anticanres.12813","volume":"38","author":"T Sprave","year":"2018","unstructured":"Sprave T, Verma V, F\u00f6rster R, Schlampp I, Hees K, Bruckner T, et al. Quality of life and radiation-induced late toxicity following intensity-modulated versus three-dimensional conformal radiotherapy for patients with spinal bone metastases: results of a randomized trial. Anticancer Res. 2018;38:4953\u201360.","journal-title":"Anticancer Res"},{"key":"1422_CR25","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346.","journal-title":"J Clin Oncol"},{"key":"1422_CR26","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875\u201384.","journal-title":"J Clin Oncol"},{"key":"1422_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/annonc\/mdy012","volume":"29","author":"HS Rugo","year":"2018","unstructured":"Rugo HS, Di\u00e9ras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29:888\u201394.","journal-title":"Ann Oncol"},{"key":"1422_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.07.1673","volume":"102","author":"R Kalash","year":"2018","unstructured":"Kalash R, Iarrobino NA, Beriwal S, Sun M, Glaser SM, Champ CE. Palbociclib enhances pulmonary fibrosis in patients undergoing thoracic radiation therapy: a case series and review of the literature. Int J Radiat Oncol Biol Phys. 2018;102: e610.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-022-01422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-022-01422-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-022-01422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T16:23:31Z","timestamp":1677169411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-022-01422-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1422"],"URL":"https:\/\/doi.org\/10.1007\/s12282-022-01422-5","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"24 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study was obtained from all patients. The study protocol was approved by the participating centers\u2019 institutional review boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}